Sanofi Group Director, Global Market Access and Pricing (MAx) for Rilzabrutinib (Rare Blood Disorders) in Cambridge, Massachusetts
S/he will be a key contributor to the Rare Blood Disorders (RBD) Business Unit.
S/he will focus on all markets including US, EU, JPAC, and International in order to ensure a globally aligned worldwide strategy and execution.
This individual will coordinate a cross-functional matrixed team including health economics, pricing, public affairs, and communication.
S/he will report to the MAx lead Rare Blood Disorders - Fitusiran & Complement disorders.
Represent payer’s viewpoint within cross-functional, cross-regional commercialization teams including Marketing, Medical, Clinical Development, Regulatory, HEVA, Pricing, Communications, Policy/Advocacy, and Public Affairs, thereby optimizing the launch of Rilzabrutinib in PV and ITP indications
Provide the payer’s perspective for the prioritization of future indications in RBD as well as in other therapeutic areas
Work cross-functionally with HEVA and Clinical Development to provide input on payer needs in trial design for these future indications
Partner effectively with global support functions and countries to execute on core MAx deliverables (MAx blueprint, Global value story, Global pricing policy informed by pricing research, contracting strategy including value-based and outcomes-based frameworks, launch sequencing, negotiation guide and objection handler)
Coordinate closely with the HEOR/HEVA lead to ensure deliverables alignment (e.g. pricing strategy with budget impact / cost-effectiveness model; payer value story with core value dossier, etc.) and identify evidence generation strategies to ensure optimal pricing and market access for Rilzabrutinib
Contribute to the internal governance reviews (TARC, DWG, IDCC, GMAx Committee, etc.) related to the brand
Lead the MAx strategy implementation in all launching markets according to the “Glocal” model by partnering with country MAx leads to anticipate local payer challenges and ensure strategy execution
Work with country MAx leads to ensure deliverables incorporate country feedback, are optimally positioned to support payer negotiations, and are provided in a timeframe consistent with dossier submission
Lead payer negotiation workshops to prepare for launch and build resulting negotiation guide and objection handler to assist in country payer interactions
Provide a consistent approach to preparing affiliates for pricing and access negotiations; Ensure with appropriate functions the MAx readiness of countries & support as needed (e.g. negotiations, sharing of best practices, etc.)
In conjunction with the commercial team, conduct reviews of country business cases for launching markets to approve payer submission and launch; identify opportunities for improvement and work with markets to strengthen country submissions
Provide market access and pricing input into forecasts including strategic, operational and financial forecasting
BA/BS and 5+ years of relevant professional experience including market access, pricing & reimbursement, health economics
5+ years of experience at local &/or international level w/ knowledge of global market access & payer environment
Previous launch experience in a competitive landscape is a plus
Knowledge of rare disease / rare blood disorders is appreciated, but other backgrounds are welcomed especially if experience with multi-indications assets
Demonstrated ability to take on highly complex business environments, recommend strategic and tactical solutions in a simple and straightforward manner
Exhibits outstanding written and oral communication skills, including the ability to effectively write and deliver presentations to professionals at all levels within Sanofi
Demonstrated relationship building at all levels of the organization and across geographies
About Sanofi Genzyme:
Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.
Sanofi Inc. and its U.S. affiliates are Equal Opportunity and Affirmative Action employers committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status; domestic violence victim status; atypical cellular or blood trait; genetic information (including the refusal to submit to genetic testing) or any other characteristic protected by law.
At Sanofi diversity and inclusion is foundational to how we operate and embedded in our Core Values. We recognize to truly tap into the richness diversity brings we must lead with inclusion and have a workplace where those differences can thrive and be leveraged to empower the lives of our colleagues, patients and customers. We respect and celebrate the diversity of our people, their backgrounds and experiences and provide equal opportunity for all.